There are currently 224 clinical trials in Santa Monica, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Clinical Science Institute, Sarcoma Oncology Center, Citruslabs and John Wayne Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692
Recruiting
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Providence Saint John's Health Center, Santa Monica, California
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, Colorectal Cancer (MSI-H), MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer
Register for Updates
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT04008797
Recruiting
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: UCLA University of California - Los Angeles, Santa Monica, California
Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Register for Updates
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Recruiting
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: the recommended dose for Phase 2 to evaluate the safety and tolerability of the combination therapy to determine the pharmacokinetics of TNG260 to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: UCLA Hematology/Oncology, Santa Monica, California
Conditions: Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer, Pancreatic Cancer, Cervical Cancer, Breast Cancer, Carcinoma of Unknown Primary
Register for Updates
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555
Recruiting
This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/22/2024
Locations: Research Site, Santa Monica, California
Conditions: Non-Small Cell Lung Cancer
Register for Updates
M6®-C Artificial Cervical Disc Two-Level IDE Pivotal Study
NCT04982835
Recruiting
Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/22/2024
Locations: Institute of Neuro Innovation, Santa Monica, California
Conditions: Cervical Disc Degenerative Disorder
Register for Updates
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
NCT04960709
Recruiting
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplantin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin in terms of efficacy a... Read More
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
03/21/2024
Locations: Research Site, Santa Monica, California
Conditions: Muscle Invasive Bladder Cancer
Register for Updates
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT06138613
Recruiting
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/20/2024
Locations: Santa Monica Clinical Trials, Santa Monica, California
Conditions: Motion Sickness
Register for Updates
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05361707
Recruiting
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
Gender:
All
Ages:
Between 2 years and 65 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Santa Monica, California
Conditions: Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
Register for Updates
A Study of XMT-1660 in Participants With Solid Tumors
NCT05377996
Recruiting
A Study of XMT-1660 in Solid Tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: UCLA, Santa Monica, California
Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
Register for Updates
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT05903924
Recruiting
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2024
Locations: Santa Monica Clinical Trials, Santa Monica, California
Conditions: Motion Sickness
Register for Updates
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT05425940
Recruiting
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Exelixis Clinical Site #80, Santa Monica, California
Conditions: Colorectal Cancer
Register for Updates
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577
Recruiting
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall... Read More
Gender:
Male
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2024
Locations: Research Site, Santa Monica, California
Conditions: Prostate Cancer
Register for Updates